Longevity drugs address age-related diseases
Over the last decade, researchers have honed in on the fundamental underlying changes at a cellular and genetic level in the aging process. We now have clarity that less than ten categories of damage are responsible for the breakdown of cellular machinery as we age.
The first drugs and therapies that target these age-related breakdowns in our cellular machinery will come to market towards the end of this decade. We do not yet have conclusive evidence that they slow the aging process, but, by targeting the underlying mechanisms of aging, these drugs prove themselves effective against age-related diseases such as cardiovascular disease, stroke, cancers, metabolic diseases, and neurodegeneration.
You can read more at our blog in our overview of aging and why we invested in Elevian.